Candriam S.C.A. Increases Holdings in Celcuity, Inc. $CELC

Candriam S.C.A. increased its position in Celcuity, Inc. (NASDAQ:CELC) by 48.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 390,924 shares of the company’s stock after purchasing an additional 127,348 shares during the quarter. Candriam S.C.A. owned approximately 0.92% of Celcuity worth $19,312,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CELC. Soleus Capital Management L.P. lifted its holdings in shares of Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after buying an additional 437,696 shares during the period. Eventide Asset Management LLC raised its holdings in shares of Celcuity by 9.8% in the second quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after acquiring an additional 123,774 shares in the last quarter. Saturn V Capital Management LP raised its holdings in shares of Celcuity by 8.4% in the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after acquiring an additional 91,843 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Celcuity by 27.6% in the second quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock worth $10,263,000 after acquiring an additional 166,324 shares during the period. Finally, Captrust Financial Advisors lifted its stake in Celcuity by 2.3% in the second quarter. Captrust Financial Advisors now owns 570,441 shares of the company’s stock worth $7,615,000 after acquiring an additional 12,838 shares during the period. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on CELC. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Wolfe Research initiated coverage on shares of Celcuity in a research note on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective on the stock. Needham & Company LLC set a $95.00 price objective on shares of Celcuity in a report on Monday, October 20th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Finally, Wells Fargo & Company initiated coverage on Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.25.

Celcuity Price Performance

NASDAQ CELC opened at $107.90 on Tuesday. The firm’s fifty day simple moving average is $105.21 and its two-hundred day simple moving average is $76.54. The firm has a market capitalization of $4.99 billion, a P/E ratio of -29.40 and a beta of 0.36. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity, Inc. has a 12-month low of $7.57 and a 12-month high of $120.32.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. Analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 3,000 shares of Celcuity stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at $714,464.40. This trade represents a 30.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Dalvey sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the sale, the director directly owned 90,000 shares in the company, valued at approximately $10,802,700. This represents a 18.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 26,900 shares of company stock worth $3,094,917 in the last 90 days. Insiders own 15.78% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.